Arcutis Biotherapeutics (ARQT) News Today $13.66 -0.10 (-0.73%) Closing price 04:00 PM EasternExtended Trading$13.78 +0.12 (+0.89%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and OlderMay 22 at 2:12 PM | globenewswire.comRafferty Asset Management LLC Trims Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Rafferty Asset Management LLC reduced its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 24.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,337 shares of thMay 22 at 4:43 AM | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $104,835.57 in StockMay 21 at 6:44 AM | insidertrades.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Millennium Management LLCMillennium Management LLC lifted its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 101.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,310,163 shares of the company's stock afterMay 21 at 4:54 AM | marketbeat.com64,183 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by Focus Partners WealthFocus Partners Wealth purchased a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 64,183 shares of the company's stock, valuedMay 21 at 4:03 AM | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Deutsche Bank AGDeutsche Bank AG trimmed its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 51.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 387,536 shares of the company's stock after selling 412,49May 21 at 3:52 AM | marketbeat.comSuvretta Capital Management LLC Raises Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Suvretta Capital Management LLC lifted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,399,138 sharesMay 19 at 7:37 AM | marketbeat.comPoint72 Asset Management L.P. Acquires 1,509,136 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Point72 Asset Management L.P. raised its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 617.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,753,522 shares of the company's stockMay 19 at 5:53 AM | marketbeat.comLazard Asset Management LLC Lowers Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Lazard Asset Management LLC reduced its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 51.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 388,313 shares of the compMay 18, 2025 | marketbeat.comNorthern Trust Corp Acquires 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Northern Trust Corp raised its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 991,056 shares of the company's stock after acquiring an additional 54,541May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Raises Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Polar Capital Holdings Plc increased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,377,381 sharesMay 17, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Balyasny Asset Management L.P. acquired a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 103,141 shares of the company's stock, valMay 16, 2025 | marketbeat.comNew Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical PracticeMay 15, 2025 | globenewswire.comCubist Systematic Strategies LLC Invests $1.79 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Cubist Systematic Strategies LLC bought a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 128,248 shares of the company's stock, valued at approMay 15, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD cut its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 29.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,349 shares of the company's stock afteMay 15, 2025 | marketbeat.comJ. Goldman & Co LP Has $8.53 Million Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)J. Goldman & Co LP decreased its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 58.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 612,644 shares of the company's stock aMay 13, 2025 | marketbeat.comEnsign Peak Advisors Inc Has $33.07 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Ensign Peak Advisors Inc cut its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,374,140 shares of the company's stock after selling 42,672 shares during the period.May 13, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 768,553 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)D. E. Shaw & Co. Inc. grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 44.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,513,577 shares of the company's stock after acquiring an adMay 13, 2025 | marketbeat.comHC Wainwright Has Bullish Estimate for ARQT Q2 EarningsArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - HC Wainwright increased their Q2 2025 EPS estimates for shares of Arcutis Biotherapeutics in a report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.20) per share for the quarteMay 11, 2025 | marketbeat.comDriehaus Capital Management LLC Takes Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Driehaus Capital Management LLC acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,096,769 shares of the company's stock, valueMay 11, 2025 | marketbeat.comEquities Analysts Set Expectations for ARQT Q1 EarningsArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Arcutis Biotherapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($0.15) pMay 10, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $52,606.89 in StockMay 10, 2025 | insidertrades.comArcutis Biotherapeutics: Zoryve foam treatment resulted in major improvementsMay 9, 2025 | finance.yahoo.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Tudor Investment Corp ET ALTudor Investment Corp ET AL grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 206.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,334 shares of the company's stMay 9, 2025 | marketbeat.comRenaissance Technologies LLC Sells 181,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Renaissance Technologies LLC cut its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 94.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,099 shares of the comMay 9, 2025 | marketbeat.comCercano Management LLC Purchases New Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Cercano Management LLC acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,255,365 shares of the company'sMay 8, 2025 | marketbeat.comArcutis Biotherapeutics, Inc.: Arcutis Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finanznachrichten.deArcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association DermatologyMay 7, 2025 | globenewswire.comWhat To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 EarningsMay 7, 2025 | finance.yahoo.comArcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comArcutis Biotherapeutics stock falls despite Q1 revenue beatMay 6, 2025 | investing.comArcutis Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 6, 2025 | globenewswire.comFreestone Grove Partners LP Invests $499,000 in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Freestone Grove Partners LP acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 35,818 shares of the company's stock, valued at approximatelyMay 6, 2025 | marketbeat.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 5,030 Shares of StockMay 6, 2025 | insidertrades.comFirst Trust Advisors LP Takes Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)First Trust Advisors LP purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 263,137 shares of the company's stock, valued at approximately $3,665,000. FirstMay 5, 2025 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.com100,000 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Bought by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. purchased a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 100,000 shares of the company's stock, vaMay 2, 2025 | marketbeat.comArcutis Biotherapeutics (ARQT) Expected to Announce Quarterly Earnings on TuesdayArcutis Biotherapeutics (NASDAQ:ARQT) will be releasing its Q1 2025 earnings after the market closes on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-arcutis-biotherapeutics-inc-stock/)May 1, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Boosts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Gilder Gagnon Howe & Co. LLC grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,902,991 shares of the company's stock afApril 28, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Moderate Buy" by AnalystsArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a bApril 28, 2025 | marketbeat.comEversept Partners LP Trims Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Eversept Partners LP reduced its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 72.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 191,158 shares ofApril 24, 2025 | marketbeat.comPeak6 LLC Purchases Shares of 20,000 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Peak6 LLC acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,000 shares of the company's stock, valuedApril 24, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 4.1% - What's Next?Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.1% - What's Next?April 23, 2025 | marketbeat.comMYDA Advisors LLC Boosts Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)MYDA Advisors LLC raised its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 17.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 200,000 shares of the company's stock after purchaApril 22, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Bought by Invesco Ltd.Invesco Ltd. lifted its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 20.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,126,668 shares of the company's stock after acquiring an additional 188,184 shares durinApril 22, 2025 | marketbeat.comArcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial AssetsApril 19, 2025 | seekingalpha.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.7% - Should You Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 4.7% - Here's WhyApril 17, 2025 | marketbeat.comArcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025April 17, 2025 | globenewswire.comTrexquant Investment LP Sells 32,546 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Trexquant Investment LP trimmed its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 36.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,658 shares of the company's stock after selling 3April 14, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 155,406 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)JPMorgan Chase & Co. reduced its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,141,505 shares of the company's stock aApril 14, 2025 | marketbeat.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼1.320.69▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼136▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ELAN News Today BPMC News Today BBIO News Today VRNA News Today TLX News Today TGTX News Today GRFS News Today LNTH News Today LEGN News Today AXSM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARQT Stock Free ARQT Stock Alerts